Reference range for the antim眉llerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram

详细信息    查看全文

• 作者：Scott M. Nelson ; Stamatina Iliodromiti ; Richard Fleming ; Richard Anderson ; Alex McConnachie ; Claudia-Martina Messow
• 关键词：Clinical pregnancy ; GnRH agonist ; GnRH antagonist ; luteal support ; ovarian hyperstimulation syndrome
• 刊名：Fertility and Sterility
• 出版年：February, 2014
• 年：2014
• 卷：101
• 期：2
• 页码：523-529.e1
• 全文大小：476 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Objective

To develop an optimal model and age-specific centiles for the decline in antim眉llerian hormone (AMH) as measured by the new Beckman Coulter AMH Generation II (Gen II) assay and compare this to the previous nomogram derived for the Diagnostics Systems Laboratory (DSL) assay.

Design

Multicenter retrospective population study, with validation of linear, biphasic linear, differential, power, and quadratic equations.

Setting

Two clinical pathology laboratories.

Patient(s)

A new cohort of 10,984 women aged 25 to 45 years old attending infertility clinics, randomly divided into a training cohort of 5,492 women and a validation cohort of 5,492 women, and an existing cohort of 9,601 women, who had contributed to the development and validation of a nomogram for AMH measured by the DSL assay.

Intervention(s)

Serum measurement of AMH as determined by the Beckman Coulter AMH Generation II assay in 10,984 women.

Main Outcome Measure(s)

Optimal model for the decline in AMH as measured by the AMH Gen II assay with age, with age-specific 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles.

Result(s)

A quadratic model defined as (2.431 + 0.089 * Age + 鈭?.003 * Age²) fitted the decline in AMH with age. The anticipated 40% increase in age-specific population values relative to the previously validated DSL assay nomogram was not observed.

Conclusion(s)

Age-specific reference ranges for the AMH gen II assay suggest a systematic shift in assay calibration since initial evaluation and commercial release of the AMH Gen II assay.